期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 24, 期 23, 页码 2457-2467出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v24.i23.2457
关键词
Vedolizumab; Crohn's disease; Real-world; Efficacy; Ulcerative colitis; Controlled trial; Effectiveness; Safety
The biologic antitumor necrosis factor alpha (anti-TNF alpha) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action that acts on different inflammatory pathways involved in IBD pathogenesis is appealing. Vedolizumab is a fully humanised monoclonal antibody that selectively targets alpha 4 beta 7 integrin. Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNF alpha inhibitors. This review describes the efficacy, safety, and tolerability of vedolizumab reported in both randomized, controlled, clinical trials and from real-world experience in patients with UC and CD in order to identify its place in treatment algorithms for IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据